HRP20221358T1 - Nukleinske kiseline za inhibiranje ekspresije lpa u stanici - Google Patents
Nukleinske kiseline za inhibiranje ekspresije lpa u stanici Download PDFInfo
- Publication number
- HRP20221358T1 HRP20221358T1 HRP20221358TT HRP20221358T HRP20221358T1 HR P20221358 T1 HRP20221358 T1 HR P20221358T1 HR P20221358T T HRP20221358T T HR P20221358TT HR P20221358 T HRP20221358 T HR P20221358T HR P20221358 T1 HRP20221358 T1 HR P20221358T1
- Authority
- HR
- Croatia
- Prior art keywords
- nucleic acid
- strand
- denote
- acid according
- seq
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title claims 19
- 150000007523 nucleic acids Chemical class 0.000 title claims 19
- 102000039446 nucleic acids Human genes 0.000 title claims 19
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 108091028664 Ribonucleotide Proteins 0.000 claims 10
- 239000002336 ribonucleotide Substances 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- -1 alkylene ether Chemical group 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 101150091521 lpa gene Proteins 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Nukleinska kiselina za inhibiranje ekspresije LPA u stanici, naznačena time, da sadrži najmanje jednu dupleks regiju koja sadrži barem dio prve niti i barem dio druge niti koja je barem djelomično komplementarna prvoj niti, pri čemu navedena prva nit je barem djelomično komplementarna barem dijelu RNA koja je transkribirana iz LPA gena, gdje navedena prva nit sadrži nukleotidni slijed:
5' mA (ps) fU (ps) mA fA mC fU mC fU mG fU mC fC mA fU mU fA mC (ps) fC (ps) mG 3' (SEQ ID NO: 165),
i gdje navedena druga nit sadrži nukleotidni slijed:
5' mC mG mG mU mA mA fU fG fG mA mC mA mG mA mG mU mU (ps) mA (ps) mU 3' (SEQ ID NO: 163);
pri čemu fA, fC, fG i fU označavaju 2'-deoksi-2'-fluoro ribonukleotide;
mA, mC, mG i mU označavaju 2'-O-metil ribonukleotide; i
(ps) označava fosforotioatni poveznik.
2. Nukleinska kiselina prema patentnom zahtjevu 1, naznačena time, da se prva nit sastoji od nukleotidnog slijeda:
5' mA (ps) fU (ps) mA fA mC fU mC fU mG fU mC fC mA fU mU fA mC (ps) fC (ps) mG 3' (SEQ ID NO: 165);
pri čemu fA, fC, fG i fU označavaju 2'-deoksi-2'-fluoro ribonukleotide;
mA, mC, mG i mU označavaju 2'-O-metil ribonukleotide; i
(ps) označava fosforotioatni poveznik.
3. Nukleinska kiselina prema patentnom zahtjevu 1 ili zahtjevu 2, naznačena time, da se druga nit sastoji od nukleotidnog slijeda:
5' mC mG mG mU mA mA fU fG fG mA mC mA mG mA mG mU mU (ps) mA (ps) mU 3' (SEQ ID NO: 163);
pri čemu fA, fC, fG i fU označavaju 2'-deoksi-2'-fluoro ribonukleotide;
mA, mC, mG i mU označavaju 2'-O-metil ribonukleotide; i
(ps) označava fosforotioatni poveznik.
4. Nukleinska kiselina prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je nukleinska kiselina konjugirana na ligand.
5. Nukleinska kiselina prema patentnom zahtjevu 4, naznačena time, da ligand sadrži (i) jedan ili više ostataka N-acetil galaktozamin (GalNAc) skupine ili njihovih derivata, i (ii) poveznik, gdje poveznik konjugira najmanje jedan ostatak GalNAc skupine ili njegov derivat na nukleinsku kiselinu.
6. Nukleinska kiselina prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da nukleinska kiselina koja je konjugirana na ligand, sadrži spoj formule (I):
[S-X1-P-X2]3-A-X3- (I)
u kojoj:
S predstavlja saharid, poželjno gdje saharid je N-acetil galaktozamin;
X1 predstavlja C3-C6 alkilen ili (-CH2-CH2-O)m(-CH2)2- gdje m je 1, 2 ili 3;
P je fosfat ili modificirani fosfat, poželjno tiofosfat;
X2 je alkilen ili alkilen eter formule (-CH2)n-O-CH2- gdje n = 1-6;
A je jedinica grananja;
X3 predstavlja jedinicu premoštenja;
pri čemu je nukleinska kiselina koja je definirana u bilo kojem od patentnih zahtjeva 1 do 5, konjugirana na X3 preko fosfata ili modificiranog fosfata, poželjno tiofosfata, i nukleinska kiselina je poželjno konjugirana na X3 preko 5' kraja druge niti.
7. Nukleinska kiselina prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je nukleinska kiselina konjugirana na ligand i posjeduje sljedeću strukturu:
[image]
pri čemu Z je nukleinska kiselina prema bilo kojem od prethodnih patentnih zahtjeva i ligand je poželjno konjugiran na 5' kraj druge niti.
8. Nukleinska kiselina prema bilo kojem od patentnih zahtjeva 4 do 7, naznačena time, da druga nit sadrži nukleotidni slijed:
5' [ST23 (ps)]3 C6XLT (ps) mC mG mG mU mA mA fU fG fG mA mC mA mG mA mG mU mU (ps) mA (ps) mU 3' (SEQ ID NO: 164);
pri čemu fA, fC, fG i fU označavaju 2'-deoksi-2'-fluoro ribonukleotide;
mA, mC, mG i mU označavaju 2'-O-metil ribonukleotide; i
(ps) označava fosforotioatni poveznik; i
[ST23 (ps)]3 C6XLT (ps) označava:
[image]
9. Nukleinska kiselina prema patentnom zahtjevu 8, naznačena time, da se druga nit sastoji od nukleotidnog slijeda:
5' [ST23 (ps)]3 C6XLT (ps) mC mG mG mU mA mA fU fG fG mA mC mA mG mA mG mU mU (ps) mA (ps) mU 3' (SEQ ID NO: 164);
pri čemu fA, fC, fG i fU označavaju 2'-deoksi-2'-fluoro ribonukleotide;
mA, mC, mG i mU označavaju 2'-O-metil ribonukleotide; i
(ps) označava fosforotioatni poveznik; i
[ST23 (ps)]3 C6XLT (ps) označava:
[image]
10. Pripravak, naznačen time, da sadrži nukleinsku kiselinu prema bilo kojem od patentnih zahtjeva 1 do 9, i opcionalno, prijenosno sredstvo za raspodjelu i/ili fiziološki prihvatljivo pomoćno sredstvo i/ili nosač i/ili razrjeđivač i/ili pufer i/ili konzervans, pri čemu je za uporabu kao medikament.
11. Pripravak za uporabu prema patentnom zahtjevu 10, naznačen time, da je navedeni pripravak za uporabu u prevenciji ili liječenju ili smanjenju rizika bolesti ili patologije, pri čemu bolest ili patologija je kardiovaskularna bolest.
12. Pripravak za uporabu prema patentnom zahtjevu 11, naznačen time, da kardiovaskularna bolest je moždani udar, ateroskleroza, tromboza, koronarna srčana bolest ili stenoza aorte i/ili bilo koja druga bolest ili patologija koja je povezana s povišenim razinama Lp(a) čestica.
13. Farmaceutski pripravak, naznačen time, da sadrži nukleinsku kiselinu prema bilo kojem od patentnih zahtjeva 1 do 9, i nadalje sadrži prijenosno sredstvo za raspodjelu i/ili fiziološki prihvatljivo pomoćno sredstvo i/ili nosač i/ili razrjeđivač.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2018/081106 WO2019092283A1 (en) | 2017-11-13 | 2018-11-13 | Nucleic acids for inhibiting expression of lpa in a cell |
| EP19174466 | 2019-05-14 | ||
| EP19801033.2A EP3880818B1 (en) | 2018-11-13 | 2019-11-13 | Nucleic acids for inhibiting expression of lpa in a cell |
| PCT/EP2019/081158 WO2020099476A1 (en) | 2018-11-13 | 2019-11-13 | Nucleic acids for inhibiting expression of lpa in a cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221358T1 true HRP20221358T1 (hr) | 2022-12-23 |
Family
ID=66554180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221358TT HRP20221358T1 (hr) | 2018-11-13 | 2019-11-13 | Nukleinske kiseline za inhibiranje ekspresije lpa u stanici |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20220002722A1 (hr) |
| EP (2) | EP3880818B1 (hr) |
| JP (1) | JP7245328B2 (hr) |
| KR (1) | KR102553386B1 (hr) |
| CN (1) | CN113227372A (hr) |
| AU (1) | AU2019380628A1 (hr) |
| BR (1) | BR112021009213A2 (hr) |
| CA (1) | CA3119239C (hr) |
| CL (1) | CL2021001225A1 (hr) |
| CO (1) | CO2021007372A2 (hr) |
| CR (1) | CR20210301A (hr) |
| DK (1) | DK3880818T3 (hr) |
| EA (1) | EA202190895A1 (hr) |
| ES (1) | ES2932295T3 (hr) |
| FI (1) | FI3880818T3 (hr) |
| HR (1) | HRP20221358T1 (hr) |
| HU (1) | HUE060703T2 (hr) |
| IL (1) | IL283159A (hr) |
| LT (1) | LT3880818T (hr) |
| MA (1) | MA58208B1 (hr) |
| MX (1) | MX2021005590A (hr) |
| PE (1) | PE20211282A1 (hr) |
| PH (1) | PH12021550801A1 (hr) |
| PL (1) | PL3880818T3 (hr) |
| PT (1) | PT3880818T (hr) |
| RS (1) | RS63778B1 (hr) |
| SA (1) | SA521421963B1 (hr) |
| SG (1) | SG11202103882QA (hr) |
| SI (1) | SI3880818T1 (hr) |
| WO (1) | WO2020099476A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3607069T1 (sl) * | 2017-04-05 | 2023-02-28 | Silence Therapeutics Gmbh | Produkti in sestavki |
| IL274503B1 (en) | 2017-11-13 | 2024-06-01 | Silence Therapeutics Gmbh | Nucleic acids to inhibit LPA expression in the cell |
| PT3880818T (pt) | 2019-05-14 | 2022-12-06 | Silence Therapeutics Gmbh | Ácidos nucleicos para inibir a expressão de lpa numa célula |
| US20240035029A1 (en) | 2020-10-16 | 2024-02-01 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
| EP4402263A2 (en) * | 2021-09-14 | 2024-07-24 | Argonaute Rna Limited | Treatment of cardiovascular disease |
| WO2023152194A1 (en) | 2022-02-09 | 2023-08-17 | Silence Therapeutics Gmbh | Therapeutic inhibition of lpa expression |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| WO2024013334A1 (en) * | 2022-07-15 | 2024-01-18 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of agt in a cell |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| WO2024151937A1 (en) * | 2023-01-13 | 2024-07-18 | Eli Lilly And Company | Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| US20060160759A1 (en) | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
| CN101278059A (zh) * | 2005-07-28 | 2008-10-01 | 肿瘤疗法科学股份有限公司 | 诊断和治疗肾细胞癌的方法 |
| WO2009151644A2 (en) | 2008-06-13 | 2009-12-17 | Yale University | Small molecule inhibitors of autotaxin methods of use |
| AU2014284152B2 (en) * | 2013-06-21 | 2020-01-23 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| US20160272970A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| EP3228326A1 (en) * | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| SI3607069T1 (sl) | 2017-04-05 | 2023-02-28 | Silence Therapeutics Gmbh | Produkti in sestavki |
| IL274503B1 (en) * | 2017-11-13 | 2024-06-01 | Silence Therapeutics Gmbh | Nucleic acids to inhibit LPA expression in the cell |
| CA3118327A1 (en) * | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of aldh2 in a cell |
| PT3880818T (pt) | 2019-05-14 | 2022-12-06 | Silence Therapeutics Gmbh | Ácidos nucleicos para inibir a expressão de lpa numa célula |
-
2019
- 2019-11-13 PT PT198010332T patent/PT3880818T/pt unknown
- 2019-11-13 MX MX2021005590A patent/MX2021005590A/es unknown
- 2019-11-13 DK DK19801033.2T patent/DK3880818T3/da active
- 2019-11-13 HR HRP20221358TT patent/HRP20221358T1/hr unknown
- 2019-11-13 PL PL19801033.2T patent/PL3880818T3/pl unknown
- 2019-11-13 ES ES19801033T patent/ES2932295T3/es active Active
- 2019-11-13 WO PCT/EP2019/081158 patent/WO2020099476A1/en active Application Filing
- 2019-11-13 PE PE2021000650A patent/PE20211282A1/es unknown
- 2019-11-13 HU HUE19801033A patent/HUE060703T2/hu unknown
- 2019-11-13 EP EP19801033.2A patent/EP3880818B1/en active Active
- 2019-11-13 RS RS20221119A patent/RS63778B1/sr unknown
- 2019-11-13 CR CR20210301A patent/CR20210301A/es unknown
- 2019-11-13 FI FIEP19801033.2T patent/FI3880818T3/fi active
- 2019-11-13 EA EA202190895A patent/EA202190895A1/ru unknown
- 2019-11-13 BR BR112021009213-7A patent/BR112021009213A2/pt not_active Application Discontinuation
- 2019-11-13 CA CA3119239A patent/CA3119239C/en active Active
- 2019-11-13 AU AU2019380628A patent/AU2019380628A1/en active Pending
- 2019-11-13 MA MA58208A patent/MA58208B1/fr unknown
- 2019-11-13 SG SG11202103882QA patent/SG11202103882QA/en unknown
- 2019-11-13 SI SI201930387T patent/SI3880818T1/sl unknown
- 2019-11-13 KR KR1020217017471A patent/KR102553386B1/ko active IP Right Grant
- 2019-11-13 LT LTEPPCT/EP2019/081158T patent/LT3880818T/lt unknown
- 2019-11-13 CN CN201980074785.8A patent/CN113227372A/zh active Pending
- 2019-11-13 US US17/293,303 patent/US20220002722A1/en active Pending
- 2019-11-13 JP JP2021525771A patent/JP7245328B2/ja active Active
- 2019-11-13 EP EP22197500.6A patent/EP4219712A3/en active Pending
-
2021
- 2021-04-12 PH PH12021550801A patent/PH12021550801A1/en unknown
- 2021-05-06 SA SA521421963A patent/SA521421963B1/ar unknown
- 2021-05-10 CL CL2021001225A patent/CL2021001225A1/es unknown
- 2021-05-12 IL IL283159A patent/IL283159A/en unknown
- 2021-06-04 CO CONC2021/0007372A patent/CO2021007372A2/es unknown
- 2021-12-22 US US17/559,479 patent/US11499153B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221358T1 (hr) | Nukleinske kiseline za inhibiranje ekspresije lpa u stanici | |
| HRP20230127T1 (hr) | Nukleinske kiseline za inhibiranje ekspresije lpa u stanici | |
| HRP20221400T1 (hr) | Produkti i pripravci | |
| Di Fusco et al. | Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease | |
| AU2014284152B2 (en) | Compositions and methods for modulation of target nucleic acids | |
| US11260073B2 (en) | Compounds and methods for modulating C90RF72 | |
| JP2020172488A (ja) | Ｐｄ−ｌ１発現低減用のオリゴヌクレオチド | |
| KR102118429B1 (ko) | 마이크로rna 화합물 및 mir-21 활성 조절 방법 | |
| IL261901A (en) | Compositions and methods for modulating apolipoprotein expression | |
| US5994517A (en) | Ligands to enhance cellular uptake of biomolecules | |
| ES2621863T3 (es) | Compuestos de microARN y métodos para modular la actividad de miR-21 | |
| CN109475640A (zh) | 核酸被运载物的混合载运体 | |
| JP2022173554A5 (hr) | ||
| AU2017338986A1 (en) | Oligonucleotide compositions and methods thereof | |
| JP2022544587A (ja) | 結合修飾オリゴマー化合物及びその使用 | |
| JPH06510791A (ja) | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド | |
| SA519402154B1 (ar) | مترافقات أوليجومرات تخطي الإكسون للحَثَل العَضَلِيّ | |
| SA519402226B1 (ar) | مترافقات أوليجومرات تخطي الإكسون للحَثَل العَضَلِيّ | |
| CN104884618A (zh) | 寡核苷酸缀合物 | |
| CN102405286A (zh) | 减小大小的自递送RNAi化合物 | |
| JP2005518201A (ja) | 生体分子の細胞取り込みを増強するためのリガンド | |
| JP2017514489A5 (hr) | ||
| JP2017518278A5 (hr) | ||
| JP2016523515A5 (hr) | ||
| CN107083385A (zh) | 产热的miRNA调节剂 |